XML 59 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2012
Cash flows from operating activities:      
Net income $ 176,225 $ 147,139 $ 112,151
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 13,819 8,889 9,069
Loss on disposition of assets 855 8 194
Share-based compensation expense 27,068 26,612 26,275
Bad debt expense 39,235 33,294 24,742
Non-cash expense related to in-process research and development technology     750
Impairment of intangible assets   1,490  
Deferred income taxes 8,124 7,469 33,625
Unrecognized tax benefits (660) 710 560
Accreted interest on note receivable (3,337) (2,667) (2,000)
Excess tax benefit from share-based compensation (11,143) (7,888) (34,193)
Gain on sale of marketable investment securities   (165) (566)
Changes in operating assets and liabilities:      
Prepaid expenses (5,486) 757 1,204
Trade accounts receivable (24,372) (67,185) (34,986)
Other receivables (1,870) (706) (2,312)
Inventory (15,794) 6,567 (3,426)
Prepaid taxes (12,881)    
Accounts payable (1,492) 7,991 (1,249)
Accrued liabilities 3,077 11,562 11,218
Deferred revenue (1,155) (11) 748
Net cash provided by operating activities 190,213 173,866 141,804
Cash flows from investing activities:      
Capital expenditures for equipment and leasehold improvements (14,271) (11,373) (9,408)
Acquisition of Crescendo Biosciences, Inc. (see Note 12), net of cash acquired (223,531)    
Acquisition of Rules-Based Medicine, Inc., net of cash acquired     (799)
Purchase of in-process research and development technology     (750)
Purchase of other assets     (100)
Purchase of an acquisition option     (8,000)
Issuance of note receivable (Crescendo)     (17,000)
Equity investment (RainDance)   (5,000)  
Purchases of marketable investment securities (161,764) (443,777) (388,067)
Proceeds from maturities and sales marketable investment securities 381,899 384,560 385,236
Net cash used in investing activities (17,667) (75,590) (38,888)
Cash flows from financing activities:      
Net proceeds from common stock issued under share-based compensation plans 64,762 57,825 25,029
Excess tax benefit from share-based compensation 11,143 7,888 34,193
Repurchase and retirement of common stock (287,703) (146,268) (128,467)
Net cash used in financing activities (211,798) (80,555) (69,245)
Net increase (decrease) in cash and cash equivalents (39,252) 17,721 33,671
Cash and cash equivalents at beginning of year 104,073 86,352 52,681
Cash and cash equivalents at end of year 64,821 104,073 86,352
Supplemental cash flow information:      
Cash paid during the year for income taxes 108,207 80,317 33,382
Non-cash investing and financing activities:      
Fair value adjustment on marketable investment securities recorded to stockholders' equity $ (362) $ 433 $ (14)